ECM
VNRX icon

ExodusPoint Capital Management’s VolitionRx Ltd VNRX Stock Holding History

ExodusPoint Capital Management’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-995
Closed -$94K – 1675
2019
Q4 		$94K Buy
+995
New +$103K ﹤0.01% 1431

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ExodusPoint Capital Management's VNRX Position: Q1 2020 in Review

ExodusPoint Capital Management sold out of VolitionRx Ltd (VNRX) in Q1 2020, closing a stake of 995 shares — an estimated $94K sold.

ExodusPoint Capital Management first reported a position in VNRX in Q4 2019 and held it in 1 quarter. The position peaked at $94K in Q4 2019. 31 funds tracked by Wall St. Rank hold VNRX as of Q1 2020.

  • ExodusPoint Capital Management reported no remaining VolitionRx Ltd position as of Q1 2020 after selling out during the quarter.
  • ExodusPoint Capital Management sold 995 VolitionRx Ltd shares in Q1 2020, an estimated $94K.
  • ExodusPoint Capital Management first reported a position in VolitionRx Ltd in Q4 2019 and held it in 1 quarter.
  • ExodusPoint Capital Management's VolitionRx Ltd position peaked at $94K in Q4 2019.
  • 31 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q1 2020.

Based on ExodusPoint Capital Management's 13F filing for Q1 2020, filed 15 May 2020.